Benzinga | May 12, 2021 04:20PM EDT

Cyclacel Pharmaceuticals Q1 EPS $(0.50) Misses $(0.49) Estimate

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 66.22 percent increase over losses of $(1.48) per share from the same period last year.